Overall Survival
FIG 2. · Panel OS_curves
Panel OS_curves 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Naruto Taira, Satoshi Morita, Masakazu Toi, Shinji Ohno, Norikazu Masuda
J Clin Oncol 43(14) 1631-1637
In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months. Patients who have previously received pertuzumab-containing regimens as first-/second-line treatment for LA/mBC were randomly assigned 1:1 to two groups, PTC group (n = 110) and TC group (n = 109). Median OS was longer in the PTC group (median OS 36.2 v 26.5 months; hazard ratio [HR], 0.73 [one side 95% CI upper limit, 0.97]). Updated median investigator-assessed PFS (5.5 v 4.2 months; HR, 0.81 [one side 95% CI upper limit, 1.02]) were also better in the PTC group. Median PFS by independent review did not show the difference between the two groups (4.4 v 4.4 months; HR, 1.03 [one side 95% CI upper limit, 1.36]). These findings suggest that dual HER2 blockade with pertuzumab plus trastuzumab could contribute to improving OS in patients who have previously been treated with pertuzumab-containing regimens for HER2-positive LA/mBC.
2 个 Figure · 3 个 KM 面板
FIG 2. Kaplan-Meier OS curves for the intent-to-treat population. CT, computed tomography; F/U, follow-up; HR, hazard ratio; OS, overall survival; PER, pertuzumab; PTC, pertuzumab, trastuzumab and chemotherapy; TC, trastuzumab plus chemotherapy; TRA, trastuzumab.
FIG 2. · Panel OS_curves
Panel OS_curves 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 4. Kaplan-Meier survival curves for (A) updated investigator-assessed progression-free survival in the intent-to-treat population and (B) independent reviewer-assessed PFS in the centrally reviewed population. F/U, follow-up; HR, hazard ratio; PFS, progression-free survival; PTC, pertuzumab, trastuzumab, and chemotherapy; TC, trastuzumab plus chemotherapy
FIG 4. · Panel A
Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 4. · Panel B
Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。